Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LiquidiaLQDA -8.49%70 EV-to-EBIT is 36.06 as of Aug. 13, 2026. GuruFocus rates LQDA with a GF Score™ of 70/100 and a GF Value™ of $264.02 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 681 Drug Manufacturers companies, Liquidia ranks worse than 80.76% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Liquidia's Enterprise Value is $6,352.3 Mil.
Liquidia's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $176.1 Mil. Therefore, Liquidia's EV-to-EBIT for today is 36.06.
The historical rank and industry rank for Liquidia's EV-to-EBIT or its related term are showing as below:
LQDA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -83.96 Med: -6.38 Max: 150.63
Current: 36.06
During the past 10 years, the highest EV-to-EBIT of Liquidia was 150.63. The lowest was -83.96. And the median was -6.38.
LQDA's EV-to-EBIT is ranked worse than 80.76% of 681
companies
in the Drug Manufacturers industry
Industry Median: 15.76
vs LQDA: 36.06
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Liquidia's Enterprise Value for the quarter that ended in Jun. 2026 was $7,002.6 Mil.
Liquidia's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $176.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liquidia EV-to-EBIT Related Terms
Liquidia EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Liquidia's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Liquidia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liquidia EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liquidia's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Liquidia's EV-to-EBIT falls into.
Liquidia's current Enterprise Value is $6,352.3 Mil.
Liquidia's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $176.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liquidia (LQDA) has a EV-to-EBIT of 36.06 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Liquidia and its competitors. According to the industry distribution chart, Liquidia ranks #550 out of 681 companies in the Drug Manufacturers industry, placing it in the top 80.8%.
Is Liquidia's EV-to-EBIT too high?
Liquidia's current EV-to-EBIT is 36.06. The Drug Manufacturers industry median EV-to-EBIT is 15.76. Liquidia's value of 36.06 is 128.8% above this industry median. Based on the distribution chart, Liquidia ranks #550 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Liquidia has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liquidia's EV-to-EBIT compare to LNTH and ALKS?
According to the Drug Manufacturers industry distribution chart, Liquidia ranks #550 out of 681 companies for EV-to-EBIT. This places Liquidia in the lower half of its industry. The industry median EV-to-EBIT is 15.76. Liquidia's value of 36.06 is 128.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.76, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liquidia's current EV-to-EBIT of 36.06 is 128.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Liquidia and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liquidia's current EV-to-EBIT is 36.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liquidia stock overvalued right now?
Based on GuruFocus' analysis, Liquidia (LQDA) is currently considered Possible Value Trap. The stock's GF Value™ is $264.02, compared to a current price of $72.10 — trading 72.7% below its estimated fair value. The current EV-to-EBIT is 36.06 and 128.8% above the Drug Manufacturers industry median of 15.76. Liquidia's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Liquidia (LQDA), the current EV-to-EBIT is 36.06 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liquidia (LQDA) Overvalued in 2026?
Based on GuruFocus' analysis, Liquidia stock appears to be undervalued.
The current stock price of $72.10 is trading 72.7% below its estimated GF Value™ of $264.02.
GuruFocus considers Liquidia to be Possible Value Trap.
Key valuation signals for LQDA:
EV-to-EBIT: 36.06
GF Value™: $264.02 vs. price of $72.10 (72.7% below fair value)
Industry Position: 128.8% above the Drug Manufacturers median (#550 of 681)
No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
70GF Score
Get the complete analysis for LQDA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LQDA has been successfully added to your 
